Unknown

Dataset Information

0

Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways.

ABSTRACT: Malignant rhabdoid tumors (MRTs) are rare lethal tumors of childhood that most commonly occur in the kidney and brain. MRTs are driven by SMARCB1 loss, but the molecular consequences of SMARCB1 loss in extra-cranial tumors have not been comprehensively described and genomic resources for analyses of extra-cranial MRT are limited. To provide such data, we used whole-genome sequencing, whole-genome bisulfite sequencing, whole transcriptome (RNA-seq) and microRNA sequencing (miRNA-seq), and histone modification profiling to characterize extra-cranial MRTs. Our analyses revealed gene expression and methylation subgroups and focused on dysregulated pathways, including those involved in neural crest development.

SUBMITTER: Chun HE 

PROVIDER: S-EPMC5094835 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Malignant rhabdoid tumors (MRTs) are rare lethal tumors of childhood that most commonly occur in the kidney and brain. MRTs are driven by SMARCB1 loss, but the molecular consequences of SMARCB1 loss in extra-cranial tumors have not been comprehensively described and genomic resources for analyses of extra-cranial MRT are limited. To provide such data, we used whole-genome sequencing, whole-genome bisulfite sequencing, whole transcriptome (RNA-seq) and microRNA sequencing (miRNA-seq), and histone  ...[more]

Similar Datasets

Unknown Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration.
| S-EPMC6905433 | biostudies-literature
Unknown Molecular Heterogeneity in Pediatric Malignant Rhabdoid Tumors in Patients With Multi-Organ Involvement.
| S-EPMC9326117 | biostudies-literature
Unknown MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
| S-EPMC6497578 | biostudies-literature
Unknown High prevalence of SMARCB1 constitutional abnormalities including mosaicism in malignant rhabdoid tumors.
| S-EPMC7381660 | biostudies-literature
Unknown Dual Targeting of PDGFR? and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors.
| S-EPMC5098123 | biostudies-literature
Unknown Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice.
| S-EPMC17655 | biostudies-literature
Unknown p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.
| S-EPMC7876656 | biostudies-literature
Unknown Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors.
| S-EPMC9529991 | biostudies-literature
Unknown Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours.
| S-EPMC7930245 | biostudies-literature
Unknown Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.
| S-EPMC3651445 | biostudies-literature